证券代码：600257 证券简称：大湖股份 公告编号：2025-025 大湖水殖股份有限公司 2025 年半年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 重要内容提示： ●公司2025年半年度业绩预告适用"情形（一）、净利润为负值" 的应当披露业绩预告的情形。 ●经公司财务部门初步测算，预计2025年半年度实现归属于母公 司所有者的净利润为 -250万元到-450万元，实现归属于母公司所有者 的扣除非经常性损益的净利润预计为-450万元到-650万元。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 6 月 30 日 （二）业绩预告情况 预计2025年半年度实现归属于母公司所有者的扣除非经常性损益 的净利润为-450万元到-650万元。 2、本期业绩预告未经年审会计师审计。 二、上年同期经营业绩和财务状况 （一）利润总额:967.58 万元。归属于母公司所有者的净利 润:-1,378.24 万元；归属于母公司所有者的扣除非经常性损益的净利 润：-1,676.0 ...

大湖股份（600257）公告，预计2025年半年度实现归属于母公司所有者的净利润为-250万元到-450万 元，将出现亏损，同比减亏928.24万元到1128.24万元。预计2025年半年度实现归属于母公司所有者的扣 除非经常性损益的净利润为-450万元到-650万元。本次业绩预告数据系基于公司自身专业判断进行的初 步测算，未经注册会计师审计。 ...

Group 1 - The marine economy concept stocks are experiencing a strong upward trend, leading to a significant rise in the aquaculture sector [1] - Zhongshui Fishery and Kaichuang International both reached the daily limit increase, indicating strong market interest [1] - Guolian Aquatic Products rose over 10%, with other companies like Haodangjia, Zhangzidao, Dahu Co., and Jinhai Biological also seeing gains [1]

证券代码：600257 证券简称：大湖股份 公告编号：2025-024 大湖水殖股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性 承担个别及连带责任。 重要内容提示： ●根据《上海证券交易所上市公司自律监管指南第 1 号——公 告格式》的规定，大湖水殖股份有限公司（以下简称"公司"）对 2025 年年度预计担保额度范围内的担保进展情况按月度进行汇总披 露。 ●公司 2025 年年度担保额度预计范围之内的被担保人均为公司 合并报表范围内的子公司，不涉及公司关联方。 ●本月新增实际提供担保金额为人民币 900 万元，为银行贷款 合同到期后的续签担保。 ●截止本公告披露日，公司在 2025 年年度预计担保额度范围内 为下属子公司已实际累计提供的担保余额为 9,400 万元（含本月新 增担保），占公司最近一期经审计的归属于上市公司股东净资产的 比例为 11.80%。 ●在本次披露的 2025 年年度预计担保额度范围内的担保进展中， 新签担保协议不涉及反担保。 ●截止本公告披露日，公司无对外担保逾期情况。 ...

Group 1 - The high-pressure oxygen chamber concept declined by 2.26%, ranking among the top declines in concept sectors, with companies like Aoyang Health, International Medicine, and Weiao Co., Ltd. experiencing significant drops [1] - The main funds in the high-pressure oxygen chamber concept saw a net outflow of 363 million yuan, with seven stocks experiencing net outflows, led by Innovation Medical with a net outflow of 308 million yuan [2] - Other companies with notable net outflows include Aoyang Health, Dahu Co., Ltd., and Yinkang Life, with net outflows of 27.01 million yuan, 8.53 million yuan, and 6.79 million yuan respectively [2] Group 2 - The top gainers in concept sectors included the military equipment restructuring concept, which rose by 3.51%, and PCB concept, which increased by 3.29% [2] - The high-pressure oxygen chamber concept was among the sectors with the largest declines, alongside glyphosate and rare earth permanent magnets, which fell by 2.82% and 2.57% respectively [2] - The trading volume for the high-pressure oxygen chamber concept stocks showed varying turnover rates, with Innovation Medical at 36.76% and Aoyang Health at 17.53% [2]

Group 1 - The A-share aquatic product sector continues to rise, with Zhongshui Fisheries hitting the daily limit increase [1] - Other companies such as Guolian Aquatic Products, Dahu Co., Zhangzidao, Shennong Seed Industry, Baiyang Co., and Haodangjia also experienced gains [1]

Group 1 - The high-pressure oxygen chamber concept increased by 1.54%, ranking 6th among concept sectors, with five stocks rising, including Aoyang Health, which hit the daily limit, and Yingkang Life, Jinling Pharmaceutical, and International Medicine showing gains of 4.30%, 1.70%, and 0.58% respectively [1][2] - The main capital inflow into the high-pressure oxygen chamber concept was 0.52 billion yuan, with Aoyang Health receiving the highest net inflow of 68.73 million yuan, followed by Yingkang Life and Samsung Medical with net inflows of 11.24 million yuan and 9.36 million yuan respectively [2][3] - Aoyang Health, Yingkang Life, and Tiedean Heavy Industry had the highest net inflow ratios of 7.40%, 3.64%, and 3.00% respectively, indicating strong investor interest [3][4] Group 2 - The top-performing stocks in the high-pressure oxygen chamber concept included Aoyang Health with a daily increase of 10.12% and a turnover rate of 26.84%, while other notable stocks included Yingkang Life and Samsung Medical with increases of 4.30% and 0.17% respectively [3][4] - Stocks that experienced declines included Innovative Medical, Tiedean Heavy Industry, and Weiao Co., with decreases of 1.56%, 0.74%, and 0.68% respectively, indicating some volatility within the sector [1][4]

证券代码：600257 证券简称：大湖股份 公告编号：2025-023 大湖水殖股份有限公司 关于召开 2024 年年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示 ●会议召开时间：2025 年 06 月 05 日(星期四)下午 15:00-17:00 公司已于 2025 年 4 月 9 日披露公司 2024 年年度报告，为便于广 大投资者更全面深入地了解公司 2024 年度经营成果、财务状况，公 司计划于 2025 年 06 月 05 日下午 15:00-17:00 举行 2024 年年度业绩 说明会，就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以视频结合网络互动的方式召开，公司将针对 2024 年度经营成果及财务指标的具体情况与投资者进行互动交流和 沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 会议召开时间：2025 年 06 月 05 日 下午 15:00-17:00 会议召开地点：上证路演中心（http://roadshow ...

证券代码：600257 证券简称：大湖股份 公告编号：2025-022 大湖水殖股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025 年 4 月 29 日 (二)股东大会召开的地点：湖南省常德市武陵区建设东路 348 号泓鑫桃林 6 号楼 21 楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 367 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 127,808,582 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 26.5583 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由董事会召集，会议召集与召开程序符合《公司法》及《公司章程》 的相关规定，合法有效。会议由董事长罗订坤先生主持。 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥151,179,789.38, a decrease of 27.47% compared to ¥208,442,460.81 in the same period last year[4] - The net profit attributable to shareholders was -¥3,439,404.31, an improvement of 56.52% from -¥7,910,466.66 year-on-year[4] - The net cash flow from operating activities was ¥41,848,238.17, a significant recovery from -¥24,356,734.57 in the previous year[4] - The basic earnings per share improved to -¥0.007, up 56.25% from -¥0.016 in the same period last year[4] - The gross profit margin for Q1 2025 was approximately 3.5%, compared to a margin of 0.1% in Q1 2024[19] - Net profit for Q1 2025 was ¥2,446,975.84, compared to a net loss of ¥2,917,658.84 in Q1 2024[20] - The company achieved a profit before tax of ¥9,114,232.96 in Q1 2025, compared to ¥1,624,356.39 in Q1 2024[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,859,134,117.18, a slight decrease of 0.06% from ¥1,860,201,296.68 at the end of the previous year[5] - Total current assets increased slightly to ¥849,223,049.14 from ¥835,350,263.65, showing a growth of about 1.04%[14] - Total liabilities decreased slightly to ¥899,590,238.45 in Q1 2025 from ¥903,768,579.01 in Q1 2024[18] - Short-term borrowings increased to ¥240,120,425.01 from ¥200,212,711.12, reflecting a rise of about 19.93%[15] - Total current liabilities decreased slightly to ¥439,125,110.64 from ¥443,373,069.74, a decline of approximately 0.94%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 52,608[10] - The largest shareholder, Tibet Hongshan Technology Development Co., Ltd., holds 118,051,811 shares, representing 24.53% of the total shares[10] Cash Flow and Investments - The company reported a net cash flow from operating activities of ¥41,848,238.17 in Q1 2025, a significant improvement from a net outflow of ¥24,356,734.57 in Q1 2024[23] - Cash inflow from investment activities was ¥35,254,176.61 in Q1 2025, compared to ¥27,064,290.00 in Q1 2024[23] - Investment cash outflow totaled $91,606,851.28, an increase from $73,458,850.63 in the previous period, resulting in a net cash flow from investment activities of -$56,352,674.67 compared to -$46,394,560.63[24] - Cash inflow from financing activities was $80,000,000.00, up from $76,000,000.00, while cash outflow for debt repayment decreased to $40,000,000.00 from $85,000,000.00[24] - The net cash flow from financing activities improved to $35,032,119.76 from -$16,000,383.38 in the previous period[24] - The net increase in cash and cash equivalents was $20,527,683.26, contrasting with a decrease of $86,751,678.58 in the prior period[24] - The ending balance of cash and cash equivalents was $207,608,098.42, down from $249,406,302.19[24] Cost Management - Sales expenses decreased by 39.69% compared to the previous year, attributed to reduced marketing and promotional costs[8] - The company has strengthened cost control measures, contributing to the improved net profit and earnings per share[8] Other Financial Metrics - The weighted average return on equity increased by 0.47 percentage points to -0.433%[4] - Research and development expenses increased to ¥169,977.70 in Q1 2025 from ¥89,575.46 in Q1 2024, reflecting a focus on innovation[19] - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[24] Changes in Financial Assets - The company reported a 162.59% increase in trading financial assets due to the investment of idle funds in short-term bank financial products[8] - Trading financial assets rose significantly to ¥90,078,246.58 from ¥34,303,205.48, marking an increase of about 162.5%[14] - Accounts receivable decreased by 34.53%, primarily due to timely payments from supermarket channels[8] - Accounts receivable decreased to ¥88,789,425.19 from ¥135,612,695.46, a decline of approximately 34.5%[14]